Buy Rating for Oric Pharmaceuticals: Promising Developments and Enozertinib’s Potential in NSCLC Treatment

J.P. Morgan analyst Anupam Rama has maintained their bullish stance on ORIC stock, giving a Buy rating on November 20.

Anupam Rama has given his Buy rating due to a combination of factors surrounding Oric Pharmaceuticals’ promising developments. The company is set to present multiple studies on its drug enozertinib at the ESMO Asia conference, which could significantly enhance its visibility and perceived value in the market. Rama highlights the potential of enozertinib as a catalyst for long-term value creation, especially given its focus on treating various forms of NSCLC, including those with EGFR and HER2 mutations.
Moreover, the inclusion of patients with active CNS metastases in the studies is a critical factor, as it differentiates Oric’s approach from its competitors and addresses a more severe patient population. The safety profile of enozertinib, with low rates of adverse events and dose modifications, adds to the confidence in its potential. Rama is particularly optimistic about the drug’s efficacy, noting the promising objective response rates across different patient cohorts, which, despite being on the lower end of competitive benchmarks, are noteworthy given the challenging patient demographics being addressed.

In another report released on November 20, Evercore ISI also initiated coverage with a Buy rating on the stock with a $25.00 price target.